Storia in 2 fonti

AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching

Roivant's autoimmune drug approval, Cytokinetics reports full data for heart condition treatment, and more biotech news

Raccontata da

statnews.com

biopharmadive.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo1 g fa

AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching

Roivant's autoimmune drug approval, Cytokinetics reports full data for heart condition treatment, and more biotech news

originale

biopharmadive.com2 g fa

AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.

Leggi questa versione → originale

Timeline cronologica

mercoledì 26 agosto 2026·statnews.com
Key data on a new class of cardio drugs are coming
GSK's shingles vaccine, new financial investment in women's health, and more biotech news from The Readout
giovedì 27 agosto 2026·statnews.com
Alnylam's heart drug troubles take center stage at a cardiology conference
The European Society of Cardiology Congress that kicks off Friday in Munich will be a consequential meeting for Alnylam Pharmaceuticals.

AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching

AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease

Timeline cronologica

Key data on a new class of cardio drugs are coming

Alnylam's heart drug troubles take center stage at a cardiology conference

What’s in Merck and Moderna’s cancer vaccine algorithm?

AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease

AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching